According to filings with the U.S. Securities and Exchange Commission, Dewpoint Therapeutics is raising up to $59,124,298.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Dewpoint Therapeutics
Dewpoint Therapeutics is a leading biotechnology company that applies the understanding of biomolecular condensates to drug discovery, aiming to develop a new generation of therapeutics for diseases with high unmet needs. The company utilizes a fully integrated discovery platform that combines state-of-the-art experimental technologies with a powerful AI platform to develop therapies across a broad range of therapeutic areas, including oncology, neurodegenerative, cardiopulmonary, and metabolic diseases. Dewpoint has established itself as a leader in condensate biotechnology, evidenced by two groundbreaking foundational technology patents granted in 2022 and recognition such as the Fierce 15 award and being named among America’s Best Startup Employers by Forbes. With a daring vision that the dysregulation of biomolecular condensates explains the root cause of complex diseases, Dewpoint is advancing novel therapies and has forged discovery partnerships with leading global pharmaceutical companies like Bayer, Novo Nordisk, and Mitsubishi Tanabe Pharma Corporation.

To learn more about Dewpoint Therapeutics, visit https://dewpointx.com/
Dewpoint Therapeutics Linkedin Page: https://www.linkedin.com/company/dewpointtherapeutics/

Contact:
Ameet Nathwani, President and Chief Executive Officer
617-914-8448

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.